Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

Mesoblast Limited (NASDAQ:MESO – Get Free Report)’s share price hit a new 52-week high on Monday . The stock traded as high ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...

These shares are starting the year in a positive fashion. But why? The post Why Brainchip, Fortescue, Mesoblast, and QBE ...

Investors are sending the Mesoblast share price tumbling on Friday. But why? The post Why the Mesoblast share price is diving ...

Mesoblast Limited (AU:MSB) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...

Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy ...

The Weebit Nano share price is up 4% to $3.60. This gain comes despite there being no news out of the semiconductor company.

Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).

S&P/ASX All Ords Index (ASX: XAO) shares closed higher on the first day of trading for 2025, with these stocks clocking new ...

Two former internet messageboard darlings that fell from grace a few years ago have been the year's biggest winners on the ...